Angiotensin-(1-7)

Phase 1Small molecule

UUniversity of Arizona

Angiotensin-(1-7) is one of 214 small molecule programs targeting Essential Hypertension. It is currently in Phase 1.

Indications

Total Trials

Active Trials

213

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

Brain InjuryActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

HypertensionActive, not recruiting

Heart FailureActive, not recruiting

COVID-19Active, not recruiting

ObesityActive, not recruiting

Essential HypertensionPhase 1

Active, not recruiting

Brain InjuryPhase 1/Phase 2

Active, not recruiting

Peripheral Arterial DiseasePhase 1

Active, not recruiting

HypertensionPhase 1

Active, not recruiting

Heart FailurePhase 1/Phase 2

Active, not recruiting

COVID-19Phase 1/Phase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Bnt162b2

BioNTech

Preclinical

29 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Biaxin

AbbVie

Preclinical

2 5

Angiotensin-(1-7)

UUniversity of Arizona

Phase 1

4 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Obesity

NCT03777215

Phase 1Recruiting

Cardiovascular

NCT05301192

Q3 2027

Phase 1/2Recruiting

Brain Injury

NCT06282965

Q1 2029

Phase 1Recruiting

Hypertension

NCT06482853

Q4 2029

Phase 1Recruiting

Study completion

NCT02646475

Clinical

Trials by Indication[1]

COVID-194 trials

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

Withdrawn·SStanford University·Phase 1/2·NCT04570501

Angiotensin 1-7 as a Therapy in the Treatment of COVID-19

Unknown status·RRambam Health Care Campus·Phase 2·NCT04605887·120 enrolled

Use of Angiotensin-(1-7) in COVID-19

Completed·EErasme University Hospital·Phase 1/2·NCT04633772·112 enrolled

Show 1 more trial

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

Unknown status·EErasme University Hospital·Phase 2/3·NCT04332666·60 enrolled

Heart Failure2 trials

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

Suspended·UUniversity of Arizona·Phase 2·NCT03159988·6 enrolled

Biomarker Study: Heart Failure Patients at Risk

Unknown status·UUniversity of Arizona·Phase 1/2·NCT05336175·40 enrolled

Hypertension2 trials

Angiotensin 1-7 in Obesity Hypertension

Terminated·AAmy Arnold·Phase 1·NCT03604289·8 enrolled

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Recruiting·MMilton S. Hershey Medical Center·Phase 1·NCT06482853·52 enrolled

Hypertensive1 trial

Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects

Unknown status·IInstituto de Cardiologia do Rio Grande do Sul·Phase 1·NCT03001271·32 enrolled

Essential Hypertension1 trial

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Terminated·VVanderbilt University·Phase 1·NCT02245230·24 enrolled

8 more indications

ART1 trial

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

Terminated·UUS Biotest, Inc.·Phase 1·NCT00757250·13 enrolled

Obesity1 trial

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

Active, not recruiting·AAmy Arnold·Phase 1·NCT03777215·30 enrolled

Autonomic Failure1 trial

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Terminated·VVanderbilt University Medical Center·Phase 1·NCT02591173·7 enrolled

Brain Injury1 trial

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

Recruiting·UUniversity of Arizona·Phase 1/2·NCT06282965·90 enrolled

Peripheral Arterial Disease1 trial

Angiotensin-(1-7) in Peripheral Arterial Disease

Terminated·MMilton S. Hershey Medical Center·Phase 1·NCT03240068·6 enrolled

Cardiovascular1 trial

Angiotensin-(1-7) Cardiovascular Effects in Aging

Recruiting·MMilton S. Hershey Medical Center·Phase 1·NCT05301192·26 enrolled

Safety and Efficacy1 trial

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

Terminated·UUniversity of Arizona·Phase 2·NCT03252093·6 enrolled

Unspecified1 trial

Metabolic Effects of Angiotensin-(1-7)

Recruiting·VVanderbilt University·Phase 1·NCT02646475·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Angiotensin-(1-7). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Angiotensin-(1-7) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Angiotensin-(1-7). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Arizona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Arizona

Angiotensin-(1-7)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q1 2029

Q4 2029

Trials by Indication[1]

COVID-194 trials

Heart Failure2 trials

Hypertension2 trials

Hypertensive1 trial

Essential Hypertension1 trial

ART1 trial

Obesity1 trial

Autonomic Failure1 trial

Brain Injury1 trial

Peripheral Arterial Disease1 trial

Cardiovascular1 trial

Safety and Efficacy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News